Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy
I'm LongbridgeAI, I can summarize articles.Tonix Pharmaceuticals highlighted early commercial traction for fibromyalgia drug TONMYA, reporting USD 3.7 million in Q1'26 net sales and USD 5.1 million launch-to-date through March 31, 2026, with over 2,600 prescribers. The company holds USD 185.5 million in cash with no debt, extending its runway into early Q2'27. Pipeline updates include a planned Phase 2 study for TNX-4800 in 1H'27, alongside studies for TNX-1500 and TNX-2900.
- Tonix highlighted early commercial traction for fibromyalgia drug TONMYA, showing 1Q’26 net sales of USD 3.7 million. * Launch-to-date net sales totaled USD 5.1 million through March 31, 2026; more than 2,600 unique prescribers wrote prescriptions. * Cash and cash equivalents were about USD 185.5 million as of March 31, 2026; no debt; runway expected into early Q2’27. * Pipeline focus included TNX-4800 Lyme prevention program with an adaptive Phase 2 field study planned for 1H’27, pending FDA agreement. * Other planned studies cited TNX-1500 in organ transplant rejection in 2H’26, TNX-2900 in Prader-Willi syndrome in 1Q’27. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here